-- Scott Roberts
THURSDAY, April 7 (HealthDay News) -- Horizant extended release
tablets (gabapentin enacarbil) have been approved as a once-daily
treatment for restless legs syndrome (RLS), a disorder that causes
a strong desire to move the legs.
The disorder creates unpleasant sensations in the legs,
including itching, tingling, burning or aching, which are
temporarily relieved by moving the legs. A person with RLS usually
has these sensations when inactive, typically in the early morning
and evening, the FDA said in a news release.
Horizant was evaluated in a pair of 12-week trials among adults
with moderate-to-severe RLS. People who took the drug reported
improvement in RLS symptoms, compared to those who took an inactive
The drug's common side effects include drowsiness and dizziness,
which could impair a person's ability to drive or use heavy
machinery. The body absorbs Horizant as gabapentin, a drug used to
treat epilepsy. Horizant's label will include a warning that drugs
used to treat epilepsy may lead to suicidal thoughts and actions in
some people, the FDA said.
Horizant was developed by drugmakers GlaxoSmithKline and
The U.S. National Institute of Neurological Disorders and Stroke
has more about
restless legs syndrome.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.